The Food and Drug Administration today released for public comment a revised draft memorandum of understanding for states regarding interstate distribution of “inordinate amounts” of compounded drugs by licensed pharmacists or physicians. Under the prior draft, issued in 2015 and on which AHA commented, inordinate amounts was defined as equal to or greater than 30 percent of all drug products dispensed or distributed by the compounder. “Some were worried that this provision could impede patients’ access to compounded drugs for which they have a medical need,” said FDA Commissioner Scott Gottlieb, M.D. Under the revised draft, states would agree to identify compounders that distribute more than 50 percent of their total prescription orders for compounded drugs interstate and report certain information to the FDA about those compounders. The draft MOU will be published in the Sept. 10 Federal Register with comments accepted for 90 days.

Related News Articles

Headline
Hospitals spend close to $360 million each year to manage drug shortages, according to a study released this week by Vizient Inc.
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.